EA201891709A1 - Антигенсвязывающие белки, связывающие pd-l1 - Google Patents

Антигенсвязывающие белки, связывающие pd-l1

Info

Publication number
EA201891709A1
EA201891709A1 EA201891709A EA201891709A EA201891709A1 EA 201891709 A1 EA201891709 A1 EA 201891709A1 EA 201891709 A EA201891709 A EA 201891709A EA 201891709 A EA201891709 A EA 201891709A EA 201891709 A1 EA201891709 A1 EA 201891709A1
Authority
EA
Eurasian Patent Office
Prior art keywords
binding
antigensbinking
proteins
higher yields
antibodies
Prior art date
Application number
EA201891709A
Other languages
English (en)
Other versions
EA037855B1 (ru
Inventor
Хэюэ Чжоу
Original Assignee
Сорренто Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сорренто Терапьютикс, Инк. filed Critical Сорренто Терапьютикс, Инк.
Publication of EA201891709A1 publication Critical patent/EA201891709A1/ru
Publication of EA037855B1 publication Critical patent/EA037855B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)

Abstract

Описаны антитела класса IgG к PD-L1, для которых существует улучшенная возможность производства с более высокими выходами. Более конкретно, описаны антитела человека, связывающие PD-L1, связывающие PD-L1 фрагменты, которые могут быть получены с более высокими выходами.
EA201891709A 2016-01-29 2017-01-27 Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1 EA037855B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288912P 2016-01-29 2016-01-29
PCT/US2017/015429 WO2017132562A1 (en) 2016-01-29 2017-01-27 Antigen binding proteins that bind pd-l1

Publications (2)

Publication Number Publication Date
EA201891709A1 true EA201891709A1 (ru) 2019-01-31
EA037855B1 EA037855B1 (ru) 2021-05-27

Family

ID=59386438

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891709A EA037855B1 (ru) 2016-01-29 2017-01-27 Полностью человеческое антитело класса igg, связывающееся с эпитопом pd-l1

Country Status (17)

Country Link
US (4) US10118963B2 (ru)
EP (1) EP3408400B1 (ru)
JP (3) JP6883590B2 (ru)
KR (2) KR102927822B1 (ru)
CN (2) CN116333124A (ru)
AU (1) AU2017212717B2 (ru)
BR (1) BR112018015480A2 (ru)
CA (1) CA3013051A1 (ru)
CL (1) CL2018002034A1 (ru)
EA (1) EA037855B1 (ru)
ES (1) ES2986360T3 (ru)
IL (1) IL260846B2 (ru)
MX (2) MX2018009228A (ru)
PH (1) PH12018501611A1 (ru)
SG (1) SG11201806496SA (ru)
TW (1) TWI760323B (ru)
WO (1) WO2017132562A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013267161A1 (en) 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
KR102927822B1 (ko) 2016-01-29 2026-02-13 주식회사유한양행 Pd-l1에 결합하는 항원 결합 단백질
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
BR112020019116A2 (pt) * 2018-03-22 2021-01-12 Keires Ag Proteínas de ligação, ácido nucleico, vetor, célula hospedeira, método de produção, proteína de ligação, composição farmacêutica e kit
US11993655B2 (en) * 2018-04-09 2024-05-28 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
WO2019227490A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and methods for imaging
WO2019228514A1 (en) 2018-06-01 2019-12-05 Tayu Huaxia Biotech Medical Group Co., Ltd. Compositions and uses thereof for treating disease or condition
US12391758B2 (en) 2018-08-20 2025-08-19 1Globe Biomedical Co., Ltd. Anti-PD-L1 cancer immunotherapy antibodies
WO2020123543A2 (en) * 2018-12-11 2020-06-18 Sanford Burnham Prebys Medical Discovery Institute Models and methods useful for the treatment of serrated colorectal cancer
WO2020151572A1 (en) 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
CN114025757B (zh) * 2019-04-18 2025-05-13 Qlsf生物治疗药物公司 人源化抗pd-l1抗体
AU2020339478A1 (en) 2019-08-29 2021-05-06 Remegen Co., Ltd. Anti PD-L1 antibody and use thereof
JP2023532279A (ja) * 2020-06-26 2023-07-27 ソレント・セラピューティクス・インコーポレイテッド 免疫調節性融合タンパク質を発現する腫瘍溶解性単純ヘルペスウイルス（ｈｓｖ）
WO2022051414A1 (en) 2020-09-02 2022-03-10 Mayo Foundation For Medical Education And Research Antibody-nanoparticle complexes and methods for making and using the same
AU2021378865A1 (en) 2020-11-16 2023-06-29 Immuneoncia Therapeutics, Inc. Biomarker for predicting therapeutic responsiveness to cancer immunotherapeutic agent and use thereof
CA3219221A1 (en) * 2021-05-07 2022-11-10 Immuneoncia Therapeutics, Inc. Bispecific antibody specifically binding to cd47 and pd-l1
CA3221925A1 (en) 2021-06-09 2022-12-15 Sorrento Therapeutics, Inc. Method of treating cancer by administration of an anti-pd-1 or anti-pd-l1 therapeutic agent via a lymphatic microneedle delivery device
JP2025532635A (ja) * 2022-09-19 2025-10-01 ソノマ バイオセラピューティクス， インコーポレイテッド 制御性ｔ細胞を標的化して化膿性汗腺炎を治療するためのシトルリン化抗原特異的キメラ抗原受容体
CN120813375A (zh) 2023-01-30 2025-10-17 凯玛布有限公司 抗体
KR20250133603A (ko) * 2024-02-29 2025-09-08 주식회사유한양행 항-tigit/항-pd-l1 이중특이적 항체 및 이의 용도
WO2025216346A1 (ko) * 2024-04-13 2025-10-16 주식회사 이뮨온시아 암 치료를 위한 pd-l1 저해제를 이용한 신보조요법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
DE69332377T2 (de) 1992-07-13 2003-07-03 Bionebraska, Inc. Verfahren zur modifizierung rekombinanter polypeptide
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
ATE516820T1 (de) 2000-09-29 2011-08-15 Schering Corp Pegyliertes interleukin 10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
CA2687368C (en) 2007-06-01 2018-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
US8877688B2 (en) * 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
AU2013267161A1 (en) * 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
BR112015007672A2 (pt) * 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AR093984A1 (es) * 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US9676853B2 (en) * 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
CA2944767C (en) 2014-04-04 2022-07-12 Mayo Foundation For Medical Education And Research Isotyping immunoglobulins using accurate molecular mass
CN105238762A (zh) * 2015-10-26 2016-01-13 无锡傲锐东源生物科技有限公司 抗pd-1蛋白单克隆抗体杂交瘤细胞及其产生的抗pd-1单克隆抗体和应用
KR102927822B1 (ko) * 2016-01-29 2026-02-13 주식회사유한양행 Pd-l1에 결합하는 항원 결합 단백질

Also Published As

Publication number Publication date
MX2022011659A (es) 2022-10-13
US20210147539A1 (en) 2021-05-20
EP3408400A4 (en) 2019-11-27
IL260846B2 (en) 2023-02-01
EP3408400A1 (en) 2018-12-05
EP3408400B1 (en) 2024-06-26
KR20190026642A (ko) 2019-03-13
IL260846A (ru) 2018-09-20
ES2986360T3 (es) 2024-11-11
WO2017132562A1 (en) 2017-08-03
US20190092861A1 (en) 2019-03-28
KR20260041830A (ko) 2026-03-27
KR102927822B1 (ko) 2026-02-13
JP2021102633A (ja) 2021-07-15
AU2017212717B2 (en) 2023-11-16
EA037855B1 (ru) 2021-05-27
US11919952B2 (en) 2024-03-05
JP6883590B2 (ja) 2021-06-09
NZ745357A (en) 2025-08-29
CA3013051A1 (en) 2017-08-03
IL260846B (en) 2022-10-01
PH12018501611A1 (en) 2019-04-08
CN109715821B (zh) 2022-09-06
SG11201806496SA (en) 2018-08-30
EP3408400C0 (en) 2024-06-26
AU2017212717A1 (en) 2018-09-06
US20240190959A1 (en) 2024-06-13
MX2018009228A (es) 2019-07-08
CN109715821A (zh) 2019-05-03
US20170218066A1 (en) 2017-08-03
BR112018015480A2 (pt) 2019-05-21
JP2022095910A (ja) 2022-06-28
TWI760323B (zh) 2022-04-11
CL2018002034A1 (es) 2019-03-15
TW201736400A (zh) 2017-10-16
JP7140867B2 (ja) 2022-09-21
WO2017132562A8 (en) 2017-09-08
US10118963B2 (en) 2018-11-06
JP2019507183A (ja) 2019-03-14
US10919964B2 (en) 2021-02-16
CN116333124A (zh) 2023-06-27

Similar Documents

Publication Publication Date Title
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
PH12018501611A1 (en) Antigen binding proteins thant bind pd-l1
PH12018502478A1 (en) Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
EP3954713A3 (en) Bispecific antibodies that bind to cd38 and cd3
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2019014576A (es) Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
EA201692394A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
MX375524B (es) Anticuerpos anti-axl.
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201791164A1 (ru) Гетеродимерные антитела, связывающие cd3 и cd38
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
HK1257056A1 (zh) 抗dll3抗体药物缀合物以及使用方法
JOP20200343A1 (ar) بروتين ربط مولد ضد مضاد لـ steap1
BR112018068678A2 (pt) anticorpos anti-mica
MX2016016883A (es) Anticuerpo anti-axl.
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
MA40527A (fr) Protéines de liaison à l'antigène se liant à wisp5
EA201591974A1 (ru) Антитела человека, связывающиеся с g-белком rsv
EA201892096A1 (ru) Нейтрализующие моноклональные антитела к il-25 и их применение
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.